Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,209
  • Shares Outstanding, K 57,487
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,850 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 2.55
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.10
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -74.97
  • Most Recent Earnings $-0.25 on 11/14/24
  • Next Earnings Date 11/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +333,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0957 +12.85%
on 12/06/24
0.1450 -25.52%
on 11/21/24
-0.0156 (-12.62%)
since 11/20/24
3-Month
0.0957 +12.85%
on 12/06/24
0.3699 -70.80%
on 10/23/24
-0.0350 (-24.48%)
since 09/20/24
52-Week
0.0955 +13.09%
on 08/16/24
70.0000 -99.85%
on 12/26/23
-49.3920 (-99.78%)
since 12/20/23

Most Recent Stories

More News
CNS Pharmaceuticals (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for brain and central nervous system cancers, will host a Virtual Analyst & Investor Day on December 11 from 11:30...

CNSP : 0.1080 (-1.82%)
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders

CNSP : 0.1080 (-1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma

CNS Pharmaceuticals (NASDAQ: CNSP) announced updated results from its ongoing pivotal trial evaluating Berubicin, a novel anthracycline crossing the blood-brain barrier, against Lomustine in recurrent...

CNSP : 0.1080 (-1.82%)
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNSP : 0.1080 (-1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting

CNS Pharmaceuticals (NASDAQ: CNSP) announced that its abstract on the pivotal trial of Berubicin, a novel treatment for glioblastoma multiforme (“GBM”), has been selected for poster presentation at...

CNSP : 0.1080 (-1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent...

CNSP : 0.1080 (-1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Berubicin’s Potential During KOL Connect Event

CNS Pharmaceuticals (NASDAQ: CNSP), focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in a Virtual Investor KOL Connect segment featuring Professor...

CNSP : 0.1080 (-1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) Secures $3 Million in Registered Direct Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into securities...

CNSP : 0.1080 (-1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) Management Participates in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company...

CNSP : 0.1080 (-1.82%)
CNS Pharmaceuticals (NASDAQ: CNSP) Announces Participation at Biotech in Europe Forum

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced...

CNSP : 0.1080 (-1.82%)

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

3rd Resistance Point 0.1376
2nd Resistance Point 0.1288
1st Resistance Point 0.1184
Last Price 0.1080
1st Support Level 0.0992
2nd Support Level 0.0904
3rd Support Level 0.0800

See More

52-Week High 70.0000
Fibonacci 61.8% 43.2965
Fibonacci 50% 35.0477
Fibonacci 38.2% 26.7990
Last Price 0.1080
52-Week Low 0.0955

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar